Oxaliplatin-induced neuropathic pain in cancer: animal models and related research progress

Yuxin Jiang, Jie Shi, Wenping Wang, Haozhe Piao, Huini Yao, Jun Yu, Zhenzhu Zhai, Qian Liu, Ningxin Li, Jiaqing Fu, Yue Shen, Shengbo Jin, Mingzhu LiFrontiers in Pharmacology 2025 · DOI

Abstract

Oxaliplatin, a third-generation platinum-based chemotherapeutic agent, has shown substantial efficacy in cancer treatment. However, its associated side effects, particularly chemotherapy-induced peripheral neuropathic pain (CIPNP), continue to challenge cancer survivors globally. Clinically, it frequently presents as numbness, coldness, and discomfort in the limbs and extremities. Duloxetine is advised for analgesic purposes. Despite its clinical relevance, both the application methods and the underlying mechanisms of oxaliplatin-induced CINP warrant further investigation. Consequently, more precise animal models are needed to explore the mechanisms and progression of this condition. This review consolidates recent advancements in rat and mouse models of oxaliplatin-induced CINP, with the aim of enhancing modeling success rates and developing models that more accurately mirror disease progression. Such models are essential for advancing clinical research and drug development.

Introduction

Oxaliplatin is a cornerstone of colorectal cancer treatment, yet its clinical utility is often hampered by severe, dose-limiting neuropathic pain, affecting up to 98% of patients. This "neurotoxic tax" manifests as chemotherapy-induced peripheral neuropathic pain (CIPNP), characterized by extreme sensitivity to cold and mechanical touch (allodynia). For many patients, the pain is so debilitating that it necessitates dosage reduction or the complete discontinuation of life-saving therapy.

A primary hurdle in developing effective treatments is the lack of a standardized animal model. Research efforts are currently fragmented, with studies utilizing diverse dosages, administration routes, and rodent strains. This review, published in Frontiers in Pharmacology, addresses this gap by synthesizing current modeling techniques and behavioral assays, providing a technical roadmap for bridging the divide between laboratory research and clinical relief.

Methodology for Model Establishment and Evaluation

The development of reliable OIPN models rests on two pillars: precise modeling techniques and robust behavioral evaluation.

1. Modeling Techniques

Researchers typically employ two types of models based on the research objective:

  • Acute Models: These involve a single high-dose injection (e.g., 6 mg/kg) to study immediate "channelopathy" effects.
  • Chronic Models: These utilize repeated low-dose injections over several weeks to mimic the cumulative toxicity observed in human clinical cycles.

While Intraperitoneal (i.p.) injection is the most common method due to its safety and ease of use, Intravenous (i.v.) administration via the caudal vein is also discussed as it more closely mirrors human clinical delivery.

2. Evaluation Assays

To quantify pain responses, several specialized behavioral tests are employed:

  • Mechanical Testing: Methods include the use of Von Frey filaments to apply calibrated pressure to the paw and the Randall-Selitto test.
  • Cold Allodynia: The Acetone Test, which measures the reaction to evaporative cooling, is a critical assay given that cold sensitivity is a hallmark of oxaliplatin toxicity.
  • Motor Coordination: Tests such as the Rotarod and grip strength assays are essential to ensure that observed responses are truly pain-related and not a result of motor deficits.
Schematic Diagram of Oxaliplatin-Induced Modeling and Evaluation in Rats/Mice

Data Synthesis and Meta-Analysis

As a comprehensive review, this work provides a meta-analysis of existing literature, standardizing parameters across various studies. The review categorizes models by species (SD and Wistar rats; C57BL/6, BALB/c, and CD-1 mice), dosage, and observed pain behaviors.

Summary of various oxaliplatin-induced modeling methods and their outcomes in rats and mice.

Key technical considerations highlighted include the choice of solvent. Oxaliplatin is unstable in chloride-containing solutions like normal saline; therefore, a 5% glucose solution is the preferred vehicle for consistent and reproducible modeling.

Mechanistic Insights and Key Results

The review identifies several critical pathways involved in OIPN:

  • Ion Channelopathy: Unlike other platinum drugs, oxaliplatin specifically targets TRPA1 and TRPV1 channels, explaining the characteristic "electric shock" sensations triggered by cold.
  • Mitochondrial Dysfunction: Chronic OIPN is largely driven by mitochondrial "overload," leading to the accumulation of reactive oxygen species (ROS) and DNA damage within the dorsal root ganglion (DRG).
  • Neuroinflammation: The activation of satellite glial cells plays a significant role in maintaining chronic pain states.

Successful modeling is typically validated when mechanical pain thresholds decrease significantly—often peaking around 10 days post-injection—and cold sensitivity increases. In humans, cumulative doses exceeding 750–850 mg/m² typically trigger chronic symptoms, while in rats, a single 6 mg/kg i.p. dose serves as a reliable benchmark for acute symptoms.

Future Directions and Limitations

Despite progress, several gaps remain. Most current studies rely on male rodents, ignoring potential sex dimorphism in pain presentation. Furthermore, while paw-withdrawal is a useful proxy, it fails to capture the complex paresthesia (numbness/tingling) reported by humans. Future research must prioritize the inclusion of both sexes and the development of an international standard for OIPN modeling to ensure cross-laboratory comparability and the successful translation of neuroprotective agents into clinical practice.

Summary updated

Abstract

Oxaliplatin, a third-generation platinum-based chemotherapeutic agent, has shown substantial efficacy in cancer treatment. However, its associated side effects, particularly chemotherapy-induced peripheral neuropathic pain (CIPNP), continue to challenge cancer survivors globally. Clinically, it frequently presents as numbness, coldness, and discomfort in the limbs and extremities. Duloxetine is advised for analgesic purposes. Despite its clinical relevance, both the application methods and the underlying mechanisms of oxaliplatin-induced CINP warrant further investigation. Consequently, more precise animal models are needed to explore the mechanisms and progression of this condition. This review consolidates recent advancements in rat and mouse models of oxaliplatin-induced CINP, with the aim of enhancing modeling success rates and developing models that more accurately mirror disease progression. Such models are essential for advancing clinical research and drug development.
BibTeX
@inproceedings{jiang2025oxaliplatin,
  author = {Yuxin Jiang and Jie Shi and Wenping Wang and Haozhe Piao and Huini Yao and Jun Yu and Zhenzhu Zhai and Qian Liu and Ningxin Li and Jiaqing Fu and Yue Shen and Shengbo Jin and Mingzhu Li},
  title = {{Oxaliplatin-induced neuropathic pain in cancer: animal models and related research progress}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1609791},
}
Figure